Wilms Tumor-1 (WT1) rs16754 Polymorphism

To the Editor,

The publication “Wilm’s tumor-1 (WT1) rs16754 Polymorphism and Clinical Outcome in Acute Myeloid Leukemia” was very interesting [1]. Ramzi et al. [1] noted that “WT1 rs16754 polymorphism may be a reliable independent prognostic factor”. In fact, the WT1 rs16754 polymorphism is proposed as an important prognostic marker for leukemia [2]. The application in the present study might be expected. However, there can also be interference effects of other polymorphisms (such as MDM2 [3] and long non-coding RNA GAS5 polymorphism [4]) that were not investigated that might modify the value of WT1 rs16754 polymorphism testing. Single polymorphism study might limit its application in clinical usage for prognosis prediction for leukemia patients.